Truquant BR Radioimmunoassay for the CA 27 data

A three-year trial tested 166 women previously treated for stage II and III cancer, demonstrating sensitivity of 57.7 percent and specificity of 97.9 percent, as reported in the Journal of Clinical Oncology. Positive predictive value was 83.3 percent, and negative predictive value was 92.6 percent. The glycoprotein product of the MUC-1 gene expressed in breast cancers is shed in the blood stream as the cancer spreads. ...